Cytokinetics Reports Third Quarter 2024 Financial Results - Cytokinetics ( NASDAQ:CYTK )
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Plan to Advance CK-089, Fast Skeletal Muscle Troponin Activator, into ...
| Ticker |
Sentiment |
Impact |
|
GOOG
|
Neutral
|
1 %
|
|
META
|
Neutral
|
1 %
|
|
CYTK
|
Somewhat Bullish
|
41 %
|
|
RPRX
|
Neutral
|
4 %
|
